These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33547876)

  • 1. Type I SMA "new natural history": long-term data in nusinersen-treated patients.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Brigati G; Tacchetti P; Salmin F; De Sanctis R; Lucibello S; Pera MC; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Clin Transl Neurol; 2021 Mar; 8(3):548-557. PubMed ID: 33547876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data.
    Pane M; Coratti G; Sansone VA; Messina S; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Brigati G; Tacchetti P; Salmin F; de Sanctis R; Lucibello S; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Neurol; 2019 Sep; 86(3):443-451. PubMed ID: 31228281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
    Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
    Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
    Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
    Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
    Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L
    Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
    Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
    N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study.
    Bishop KM; Montes J; Finkel RS
    Muscle Nerve; 2018 Jan; 57(1):142-146. PubMed ID: 28556387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen.
    Coratti G; Pane M; Lucibello S; Pera MC; Pasternak A; Montes J; Sansone VA; Duong T; Dunaway Young S; Messina S; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Tacchetti P; Carnicella S; Sframeli M; Antonaci L; Frongia AL; De Vivo DC; Darras BT; Day J; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Neuromuscul Disord; 2021 Jul; 31(7):596-602. PubMed ID: 34099377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy.
    De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E
    Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.
    Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS
    Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.